Compile Data Set for Download or QSAR
Report error Found 921 of affinity data for UniProtKB/TrEMBL: Q72502
TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271389(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[2- (benzyl...)
Affinity DataEC50:  0.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271449(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {b...)
Affinity DataEC50:  0.600nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271450(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.800nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271450(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.900nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432104(US10577353, Compound 2 | (S)-2-(tert-butoxy)-2-(4-...)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432105(US10577353, Compound 3 | (S)-2-(tert-butoxy)-2-(5-...)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432124(US10577353, Compound 19 | (S)-2-(tert-butoxy)-2-(5...)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM357255(US10214516, Compound 1)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304064(US10138253, Example 1)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271443(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271449(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {b...)
Affinity DataEC50:  1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304091(US10138253, Example 29)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM357265(US10214516, Compound 12)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432116(US10577353, Compound 11 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM357263(US10214516, Compound 9)
Affinity DataEC50:  1nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271426(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  1.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271426(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  1.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  1.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271444(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  1.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271421(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  1.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271422(4- (((3aR,5aR,5bR,7aR, 9S,11aR,11bR,13aS)- 3a-((R)...)
Affinity DataEC50:  1.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304069(US10138253, Example 6)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304083(US10138253, Example 21)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432112(US10577353, Compound 7 | (S)-2-(tert-butoxy)-2-(5-...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304087(US10138253, Example 25)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432119(US10577353, Compound 14 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432121(US10577353, Compound 16 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432120(US10577353, Compound 15 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432115(US10577353, Compound 10 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM357264(US10214516, Compound 11)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM304079(US10138253, Example 16)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM432132(US10577353, Compound 27 | (S)-2-(tert-butoxy)-2-(4...)
Affinity DataEC50:  2nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271444(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271452(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271403(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  2.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271454(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271422(4- (((3aR,5aR,5bR,7aR, 9S,11aR,11bR,13aS)- 3a-((R)...)
Affinity DataEC50:  2.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271421(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271388(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271454(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271452(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271448(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.90nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM359612(US10221156, Example 13)
Affinity DataEC50:  3nMAssay Description:A recombinant NL-RLuc proviral clone was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. Thi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetEnvelope glycoprotein gp160(Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM299214(US10125148, Example 11)
Affinity DataEC50:  3nMAssay Description:Inhibition of HIV replication. A recombinant NL-Rluc virus was constructed in which a section of the nef gene from NL4-3 was replaced with the Renill...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Displayed 1 to 50 (of 921 total ) | Next | Last >>
Jump to: